QPPV.COM KNOWLEDGE ASSESSMENT

GVP Module IX: Evidence, Causality and Clinical Context

Test your understanding of the concepts covered by GVP Module IX: Evidence, Causality and Clinical Context.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why might clinical review be needed before a quantitative analysis of a signal proceeds?

Clinical review replaces the need for statistical analysis Clinical review can identify whether apparently similar coded events represent different phenotypes or related manifestations Clinical review is needed only when no cases are available Clinical review guarantees that confounding has been eliminated

Question 2 of 10 An organisation commissions another analysis because a signal remains uncertain, but it has not identified what limitation the analysis will address. What is the main weakness?

Additional analyses are never appropriate for uncertain signals The activity is not hypothesis-driven and may add data without materially reducing uncertainty Only regulators may define evidence-generation questions Uncertainty should always be resolved using case-level causality scores

Question 3 of 10 A reviewer is comparing 10 highly documented cases with 100 poorly characterised reports. Which approach is most consistent with the article?

Treat the 100 reports as more persuasive because numerical volume is the primary measure of evidence Treat all reports as equivalent because each represents a suspected adverse reaction Assess the information content, clinical coherence and limitations of the reports rather than relying on a simple count Exclude the smaller group because rare events cannot be assessed from few cases

Question 4 of 10 What is the appropriate professional position regarding intentional rechallenge after a serious suspected adverse reaction?

It should routinely be performed to strengthen the evidence base It is unnecessary because rechallenge cannot contribute to causality assessment It may provide evidence in some circumstances, but intentional rechallenge may be inappropriate for serious reactions A positive rechallenge is required before a signal can be validated

Question 5 of 10 For a common event reported frequently among users of a medicine, what question is often most informative?

Whether the number of reports exceeds an arbitrary threshold Whether the event occurs at a different frequency, severity or pattern than in an appropriate comparator or background population Whether most reporters used the same preferred term Whether the event is already listed in the product information

Question 6 of 10 Which statement best reflects the article's position on benefit-risk assessment?

Any validated signal makes the benefit-risk balance unfavourable A causal association automatically requires withdrawal of the product The signal contributes to benefit-risk assessment, which must also consider seriousness, frequency, population, benefits, alternatives and risk minimisation Benefit-risk assessment is separate from all pharmacovigilance evidence

Question 7 of 10 What should happen when new evidence resembles the phenotype of a previously closed signal?

It should be treated as unrelated because the earlier signal was closed It should be linked to the prior assessment and considered for controlled reassessment It should be excluded from aggregate safety evaluation It should automatically reopen the signal and confirm causality

Question 8 of 10 Which factor can distort an apparent time-to-onset pattern?

Only the pharmacological half-life of the product Immortal-time effects, incomplete exposure histories, delayed diagnosis and treatment changes The existence of a comparator population A clearly defined clinical phenotype

Question 9 of 10 A product is mainly prescribed to patients with severe disease, and severe disease independently increases the risk of the event under investigation. What is the principal methodological concern?

Recall bias caused by the product label Confounding by indication A positive dechallenge Immortal-time bias caused by case reports

Question 10 of 10 What does it mean for evidence sources to be consistent in a signal assessment?

Every source must produce identical numerical estimates Only positive findings may be included The totality of findings can be explained coherently, even if individual sources differ in strength or direction All evidence sources must have the same study design

GVP Module IX: Evidence, Causality and Clinical Context

Cookie Settings